Enliven Therapeutics CFO Hohl sells $22,655 in shares

Published 14/07/2025, 22:12
Enliven Therapeutics CFO Hohl sells $22,655 in shares

Benjamin Hohl, Chief Financial Officer of Enliven Therapeutics (NASDAQ:ELVN), sold 1,000 shares of common stock on July 10, 2025, for a total of $22,655. The sales were executed in multiple trades at prices ranging from $22.59 to $22.72. The stock, currently trading at $23, has shown strong momentum with a 14.6% gain in the past week. According to InvestingPro, analysts have set price targets ranging from $33 to $52 for the $1.36 billion market cap company.

According to a Form 4 filing with the Securities and Exchange Commission, Hohl also exercised options to acquire 1,000 shares of Enliven Therapeutics common stock at an exercise price of $2.48, for a total value of $2480.

Following the transactions, Hohl directly owns 23,000 shares of Enliven Therapeutics.

The option exercise and sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 26, 2023.

In other recent news, Enliven Therapeutics has been actively engaging in several developments. The company announced a $200 million public offering, pricing 8,394,737 shares of common stock at $19.66 per share, with additional pre-funded warrants available for purchase. This offering, managed by Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho (NYSE:MFG), is expected to close around mid-June 2025. In clinical advancements, H.C. Wainwright raised its price target for Enliven Therapeutics to $48 from $40, following promising Phase 1a/1b trial results for its lead drug candidate, ELVN-001, in chronic myeloid leukemia (CML) patients. The trial showed a significant major molecular response rate, especially in patients resistant to previous treatments. Meanwhile, TD Cowen reiterated its buy rating, emphasizing the potential of ELVN-001 to become a standard therapy in the CML market, projecting peak sales of $3 billion. Additionally, Goldman Sachs initiated coverage with a buy rating and a $37 price target, citing favorable comparisons with existing treatments and a well-tolerated safety profile for ELVN-001. These developments underscore Enliven Therapeutics’ strategic efforts in advancing its clinical pipeline and securing financial resources.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.